Thrombosis in patients with immune thrombocytopenia: incidence, risk, and clinical outcomes

Goncalves, I; Lewis, C; Grainger, B; Dring, R; Lee, N; Pasricha, SR; Szer, J; Mason, K

Author(s): Goncalves, I; Lewis, C; Grainger, B; Dring, R; Lee, N; Pasricha, SR; Szer, J; Mason, K;
Details: Publication Year 2024-01,Volume 8,Issue #1,Page 102342
Journal Title: Research and Practice in Thrombosis and Haemostasis
Publication Type: Research article
Abstract: BACKGROUND: There is evidence that patients with immune thrombocytopenia (ITP) are at increased risk of thrombosis. However, the association of clinical- and treatment-related factors with thrombosis remains controversial. OBJECTIVES: To evaluate the incidence and impact of risk factors for arterial and venous thromboembolism (VTE) in patients with ITP and characterize the clinical features and management of patients. METHODS: We performed a retrospective cohort study (January 1, 2011, to October 30, 2022) of adult patients diagnosed with ITP from an Australian tertiary hospital. The incidence rates of thrombosis were calculated in terms of person-years of follow-up. Multiadjusted Cox regression was used to estimate associations. RESULTS: A total of 220 patients with 1365 person-years of follow-up since ITP diagnosis revealed 26 (11.8%) patients with a total of 37 thrombosis events, 29 (78%) VTE and 8 (22%) arterial thromboembolism (ATE). The incidence rate of thrombosis was 2.71 (95% CI, 1.97-3.72) (0.66 [95% CI, 0.33-1.26] for arterial thromboembolism and 2.05 [95% CI, 1.42-2.95] for VTE) per 100 person-years. Mean age and median time to first thrombosis diagnosis was 56 and 2.13 years, respectively. Age, secondary ITP, lines of therapy, thrombosis risk factors, and thrombopoietin receptor agonist therapy were independently associated with thrombosis. Almost all patients (25 of 26, [96%]) had good ITP disease control prior to thrombosis diagnosis, and antithrombotic therapy was deliverable and well tolerated. CONCLUSION: Diagnosis of thrombosis in patients with ITP, while infrequent, is of clinical significance. We identified from a heterogeneous real-world cohort that older patients with multiply-treated secondary ITP receiving thrombopoietin receptor agonists are at the highest risk.
Department(s): Clinical Haematology
PubMed ID: 38444612
Publisher's Version: https://doi.org/10.1016/j.rpth.2024.102342
Open Access at Publisher's Site: https://doi.org/10.1016/j.rpth.2024.102342
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-08-22 05:53:50

Last Modified: 2024-08-22 05:54:03